1. Scrip

Fruzaqla Adds Sparkle To Takeda’s First Half

Pen Helps Mainstay Entyvio

 
• By Ian Haydock

Continued growth for mainstay Entyvio and cancer newcomer Fruzaqla drove growth at Takeda in the fiscal first half, with the Japanese major brightening its outlook for the full year.

Takeda Tokyo HQ entrance
Japan now only 10% of Takeda's revenues but firm says it's committed to home market • Source: Takeda

Takeda’s 13.4% rise in reported revenue to JPY2,384.0bn ($15.63bn; +5.0% at constant currencies) in the fiscal first half was driven in large part by mainstay blockbuster Entyvio (vedolizumab).

But while the for ulcerative colitis and Crohn’s disease drug grew 10.7% to JPY473.2bn globally, and US growth (+13% at...

More from Scrip

More from Focus On Asia